Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) Stock Competitors & Peer Comparison
See CUVL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CUVL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CUVL | $5.07 | -1.55% | 252.4M | 10.79 | $0.46 | N/A |
| RPRX | $67.18 | +1.90% | 29.9B | 12.80 | $5.25 | +1.38% |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| CORT | $81.12 | -5.62% | 8.8B | 231.69 | $0.35 | N/A |
| KNSA | $92.24 | -5.45% | 7.2B | 70.96 | $1.30 | N/A |
| LQDA | $45.06 | +0.16% | 4B | 32.91 | $1.37 | N/A |
| PBH | $49.06 | +0.64% | 2.3B | 11.10 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $13.95 | -10.23% | 836.1M | -5.52 | -$2.52 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
CUVL vs RPRX Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, RPRX has a market cap of 29.9B. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while RPRX trades at $67.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas RPRX's P/E ratio is 12.80. In terms of profitability, CUVL's ROE is N/A, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CUVL is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check RPRX's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
CUVL vs WBA Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas WBA's P/E ratio is -1.64. In terms of profitability, CUVL's ROE is N/A, compared to WBA's ROE of -0.57%. Regarding short-term risk, CUVL is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check WBA's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
CUVL vs CORT Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, CORT has a market cap of 8.8B. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while CORT trades at $81.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas CORT's P/E ratio is 231.69. In terms of profitability, CUVL's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, CUVL is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check CORT's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
CUVL vs KNSA Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, KNSA has a market cap of 7.2B. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while KNSA trades at $92.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas KNSA's P/E ratio is 70.96. In terms of profitability, CUVL's ROE is N/A, compared to KNSA's ROE of +0.17%. Regarding short-term risk, CUVL is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
CUVL vs LQDA Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, LQDA has a market cap of 4B. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while LQDA trades at $45.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas LQDA's P/E ratio is 32.91. In terms of profitability, CUVL's ROE is N/A, compared to LQDA's ROE of +1.50%. Regarding short-term risk, CUVL is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
CUVL vs PBH Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, PBH has a market cap of 2.3B. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while PBH trades at $49.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas PBH's P/E ratio is 11.10. In terms of profitability, CUVL's ROE is N/A, compared to PBH's ROE of +0.09%. Regarding short-term risk, CUVL is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
CUVL vs HROWL Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas HROWL's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to HROWL's ROE of -1.04%. Regarding short-term risk, CUVL is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
CUVL vs HROWM Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas HROWM's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to HROWM's ROE of -1.04%. Regarding short-term risk, CUVL is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
CUVL vs LTGO Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, LTGO has a market cap of 836.1M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while LTGO trades at $13.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas LTGO's P/E ratio is -5.52. In terms of profitability, CUVL's ROE is N/A, compared to LTGO's ROE of N/A. Regarding short-term risk, CUVL is more volatile compared to LTGO. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check LTGO's competition here
Helus Pharma Inc. (NASDAQ: HELP)
CUVL vs HELP Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, HELP has a market cap of 656.7M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while HELP trades at $10.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas HELP's P/E ratio is -2.54. In terms of profitability, CUVL's ROE is N/A, compared to HELP's ROE of -0.71%. Regarding short-term risk, CUVL is more volatile compared to HELP. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
CUVL vs SVA Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas SVA's P/E ratio is -5.68. In terms of profitability, CUVL's ROE is N/A, compared to SVA's ROE of -0.01%. Regarding short-term risk, CUVL is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check SVA's competition here
High Tide Inc. (NASDAQ: HITI)
CUVL vs HITI Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, HITI has a market cap of 229.5M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while HITI trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas HITI's P/E ratio is -9.51. In terms of profitability, CUVL's ROE is N/A, compared to HITI's ROE of -0.36%. Regarding short-term risk, CUVL is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HITI's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
CUVL vs CELG-RI Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, CELG-RI has a market cap of 198.1M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while CELG-RI trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, CUVL is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check CELG-RI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
CUVL vs ETRA Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, ETRA has a market cap of 170.8M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while ETRA trades at $8.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas ETRA's P/E ratio is -3.04. In terms of profitability, CUVL's ROE is N/A, compared to ETRA's ROE of N/A. Regarding short-term risk, CUVL is more volatile compared to ETRA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check ETRA's competition here
TRex Bio Inc. (NASDAQ: TRXB)
CUVL vs TRXB Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, TRXB has a market cap of 112.6M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while TRXB trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas TRXB's P/E ratio is -5.47. In terms of profitability, CUVL's ROE is N/A, compared to TRXB's ROE of N/A. Regarding short-term risk, CUVL is more volatile compared to TRXB. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check TRXB's competition here
Atlantic International Corp. (NASDAQ: ATLN)
CUVL vs ATLN Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, ATLN has a market cap of 68.6M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas ATLN's P/E ratio is -0.68. In terms of profitability, CUVL's ROE is N/A, compared to ATLN's ROE of -83.20%. Regarding short-term risk, CUVL is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ATLN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
CUVL vs CTOR Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, CTOR has a market cap of 52.4M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while CTOR trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas CTOR's P/E ratio is -1.20. In terms of profitability, CUVL's ROE is N/A, compared to CTOR's ROE of -1.03%. Regarding short-term risk, CUVL is more volatile compared to CTOR. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check CTOR's competition here
Retension Pharmaceuticals Inc. (NASDAQ: RTSN)
CUVL vs RTSN Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, RTSN has a market cap of 43.8M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while RTSN trades at $11.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas RTSN's P/E ratio is -4.47. In terms of profitability, CUVL's ROE is N/A, compared to RTSN's ROE of N/A. Regarding short-term risk, CUVL is more volatile compared to RTSN. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check RTSN's competition here
Rite Aid Corporation (NYSE: RAD)
CUVL vs RAD Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas RAD's P/E ratio is -0.05. In terms of profitability, CUVL's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, CUVL is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
CUVL vs GLTO Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas GLTO's P/E ratio is -1.78. In terms of profitability, CUVL's ROE is N/A, compared to GLTO's ROE of -0.83%. Regarding short-term risk, CUVL is more volatile compared to GLTO. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check GLTO's competition here
Cosmos Health Inc. (NASDAQ: COSM)
CUVL vs COSM Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, COSM has a market cap of 31.1M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while COSM trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas COSM's P/E ratio is -0.42. In terms of profitability, CUVL's ROE is N/A, compared to COSM's ROE of -1.19%. Regarding short-term risk, CUVL is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check COSM's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
CUVL vs NSRX Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, NSRX has a market cap of 27.2M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while NSRX trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas NSRX's P/E ratio is -4.39. In terms of profitability, CUVL's ROE is N/A, compared to NSRX's ROE of -1.59%. Regarding short-term risk, CUVL is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
CUVL vs SCYX Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, SCYX has a market cap of 23.7M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while SCYX trades at $3.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas SCYX's P/E ratio is -1.10. In terms of profitability, CUVL's ROE is N/A, compared to SCYX's ROE of -0.21%. Regarding short-term risk, CUVL is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check SCYX's competition here
Pomdoctor Limited (NASDAQ: POM)
CUVL vs POM Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, POM has a market cap of 13.1M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while POM trades at $1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas POM's P/E ratio is -0.22. In terms of profitability, CUVL's ROE is N/A, compared to POM's ROE of +0.80%. Regarding short-term risk, CUVL is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check POM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
CUVL vs BFRI Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, BFRI has a market cap of 13M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while BFRI trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas BFRI's P/E ratio is -1.59. In terms of profitability, CUVL's ROE is N/A, compared to BFRI's ROE of -1.28%. Regarding short-term risk, CUVL is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check BFRI's competition here
Cerenome, Inc. (NASDAQ: CNSY)
CUVL vs CNSY Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, CNSY has a market cap of 12.8M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while CNSY trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas CNSY's P/E ratio is -0.40. In terms of profitability, CUVL's ROE is N/A, compared to CNSY's ROE of -3.94%. Regarding short-term risk, CUVL is more volatile compared to CNSY. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check CNSY's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
CUVL vs CJJD Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas CJJD's P/E ratio is -0.46. In terms of profitability, CUVL's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, CUVL is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
CUVL vs SSY Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas SSY's P/E ratio is -2.86. In terms of profitability, CUVL's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, CUVL is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check SSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
CUVL vs SCNX Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, SCNX has a market cap of 5.3M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while SCNX trades at $3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas SCNX's P/E ratio is -1.55. In terms of profitability, CUVL's ROE is N/A, compared to SCNX's ROE of -0.54%. Regarding short-term risk, CUVL is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check SCNX's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
CUVL vs BGMS Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, BGMS has a market cap of 5M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while BGMS trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas BGMS's P/E ratio is -0.25. In terms of profitability, CUVL's ROE is N/A, compared to BGMS's ROE of -0.32%. Regarding short-term risk, CUVL is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check BGMS's competition here
Eocene Ltd. (NASDAQ: EOCN)
CUVL vs EOCN Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, EOCN has a market cap of 3.1M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while EOCN trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas EOCN's P/E ratio is -0.22. In terms of profitability, CUVL's ROE is N/A, compared to EOCN's ROE of N/A. Regarding short-term risk, CUVL is more volatile compared to EOCN. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check EOCN's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
CUVL vs MDVL Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas MDVL's P/E ratio is -0.05. In terms of profitability, CUVL's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, CUVL is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check MDVL's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
CUVL vs PAVS Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, PAVS has a market cap of 2.8M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while PAVS trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas PAVS's P/E ratio is -0.04. In terms of profitability, CUVL's ROE is N/A, compared to PAVS's ROE of -0.46%. Regarding short-term risk, CUVL is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check PAVS's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
CUVL vs ATNFW Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas ATNFW's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, CUVL is more volatile compared to ATNFW. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
CUVL vs BGMSP Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, CUVL's ROE is N/A, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, CUVL is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
CUVL vs AZNH Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas AZNH's P/E ratio is 38.35. In terms of profitability, CUVL's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, CUVL is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check AZNH's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP)
CUVL vs ASBP Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, ASBP has a market cap of 944.9K. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while ASBP trades at $8.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas ASBP's P/E ratio is -0.34. In terms of profitability, CUVL's ROE is N/A, compared to ASBP's ROE of +19.93%. Regarding short-term risk, CUVL is more volatile compared to ASBP. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check ASBP's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
CUVL vs BFRIW Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, BFRIW has a market cap of 796.7K. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while BFRIW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas BFRIW's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, CUVL is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check BFRIW's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
CUVL vs LFLYW Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, CUVL's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, CUVL is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check LFLYW's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBPW)
CUVL vs ASBPW Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, ASBPW has a market cap of 149.5K. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while ASBPW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas ASBPW's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to ASBPW's ROE of +19.93%. Regarding short-term risk, CUVL is more volatile compared to ASBPW. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check ASBPW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
CUVL vs PRPH Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, PRPH has a market cap of 107.9K. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas PRPH's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to PRPH's ROE of -13.59%. Regarding short-term risk, CUVL is more volatile compared to PRPH. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check PRPH's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
CUVL vs OREX Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, OREX has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas OREX's P/E ratio is -0.14. In terms of profitability, CUVL's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, CUVL is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check OREX's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
CUVL vs ESRX Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas ESRX's P/E ratio is 10.69. In terms of profitability, CUVL's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, CUVL is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check ESRX's competition here
POZEN Inc. (NASDAQ: POZN)
CUVL vs POZN Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, POZN has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas POZN's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, CUVL is more volatile compared to POZN. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check POZN's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
CUVL vs IPXL Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas IPXL's P/E ratio is -10.11. In terms of profitability, CUVL's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, CUVL is more volatile compared to IPXL. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check IPXL's competition here
Shire plc (NASDAQ: SHPG)
CUVL vs SHPG Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas SHPG's P/E ratio is 11.35. In terms of profitability, CUVL's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, CUVL is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check SHPG's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
CUVL vs CPD Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 252.4M. In comparison, CPD has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.07 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 10.79, whereas CPD's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, CUVL is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check CPD's competition here